Communiqués Gilead Sciences, Inc.

Actions

GILD

US3755581036

Temps réel estimé Cboe BZX Autres places de cotation 20:13:02 10/06/2024			Varia. 5j.	Varia. 1 janv.
64,66 ^USD	-0,06 %		+1,94 %	-20,18 %

17:16	Arcus achève le recrutement des patients pour l'essai de phase 3 d'un régime contenant du domvanalimab pour le cancer de l'estomac	MT
06/06	Gilead déclare que les données relatives à l'association du bulevirtide et du PegIFN sont "supérieures" à celles de la monothérapie au bulevirtide ; le taux d'ARN du VHD indétectable est de 46%.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Combination therapy may hold potential for severe viral hepatitis	06/06	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	06/06	AQ
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	06/06	BU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	05/06	AQ
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	05/06	BU
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation	04/06	PU
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	03/06	BU
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	03/06	BU
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	31/05	BU
Gilead Provides Update on Phase 3 TROPiCS-04 Study	30/05	BU
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies against Novel Targets and Target Pairs	29/05	AQ
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	22/05	BU
Gilead Sciences - Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	20/05	AQ
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis	18/05	BU
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy	14/05	BU
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program	09/05	BU
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024	07/05	BU
Gilead Sciences to Present at Upcoming Investor Conferences	30/04	BU
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV	26/04	BU
Gilead: Q1 Earnings Snapshot	25/04	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Gilead Sciences, Inc.

Actions

GILD

US3755581036

Communiqués

Filtres